Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from$24, while maintaining an Overweight rating on the shares. Wells Fargo likes the risk/reward on KYV-101’s pivotal stiff person syndrome trial readout in H1 2026. The firm believes that Wall Street underappreciates how de-risked the trial is. On September 24, Kyverna Therapeutics announced that ...